E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore to Present at 34th Annual Roth Conference
March 07, 2022 16:01 ET | electroCore, Inc.
ROCKAWAY, N.J., March 07, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that its management team will...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore to Announce Fourth Quarter and Year Ended December 31, 2021 Financial Results on Thursday, March 10
March 03, 2022 08:00 ET | electroCore, Inc.
ROCKAWAY, N.J., March 03, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that it will report financial results for the...
GMILogo_Vertical-Gradient.png
U.S. Post-acute Care Market revenue worth USD 578 Billion by 2028, Says Global Market Insights Inc.
March 01, 2022 07:30 ET | Global Market Insights Inc.
Selbyville, Delaware, March 01, 2022 (GLOBE NEWSWIRE) -- U.S. post-acute care market value is poised to surpass USD 578 billion by 2028, according to a new research report by Global Market...
22157.jpg
Worldwide Neurorehabilitation Industry to 2030 - Rising Demand of Telerehabilitation Presents Opportunities
February 17, 2022 05:43 ET | Research and Markets
Dublin, Feb. 17, 2022 (GLOBE NEWSWIRE) -- The "Neurorehabilitation Market by Type, Application, and End-User: Global Opportunity Analysis and Industry Forecast, 2021-2030" report has been added to...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
Data Presented at 2022 International Stroke Congress Suggests Role for Non-invasive Vagus Nerve Stimulation (nVNS) for Treatment of Acute Stroke
February 09, 2022 08:00 ET | electroCore, Inc.
Clinical Trial (n=69) suggests safety and feasibility of nVNS for the acute treatment of stroke. Relative Ischemic Lesion Growth Decreased by 65.9% with nVNS vs. Sham Treatment. ROCKAWAY, N.J.,...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore, Inc. Announces Completion of Enrollment in the TRANSIT Study of non-Invasive Vagus Nerve Stimulation (nVNS) in Post-Operative Ileus
February 01, 2022 08:00 ET | electroCore, Inc.
ROCKAWAY, N.J., Feb. 01, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced enrollment has been completed for the TRANSIT...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore, Inc. Announces Three Abstracts to be Presented at International Stroke Conference 2022
January 25, 2022 08:00 ET | electroCore, Inc.
ROCKAWAY, N.J., Jan. 25, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced three abstracts focusing on the possible...
Dr. David Margulies and Dr. Hal C Lewis Present Healing and Regenerating the Injured Brain
Dr. David Margulies and Dr. Hal C. Lewis Present HEALING and REGENERATING the INJURED BRAIN DENVER, Jan. 19, 2022 (GLOBE NEWSWIRE) -- Talks at Google, a global talk series, recently presented Healing and Regenerating the Injured Brain with Dr. Hal Lewis and Dr. David Margulies. Drs. Lewis...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
gammaCore™ Non-Invasive Vagus Nerve Stimulation(nVNS) Receives Breakthrough Device Designation for Treatment of Posttraumatic Stress Disorder (PTSD)
January 12, 2022 08:00 ET | electroCore, Inc.
ROCKAWAY, N.J., Jan. 12, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that its gammaCore™ nVNS device has received...
E81DACBA-F17B-416E-96AA-C61EE583520F.png
electroCore, Inc. Broadens Patient Access to gammaCore with Launch of U.S. Telehealth Portal and Online Store
January 11, 2022 08:00 ET | electroCore, Inc.
ROCKAWAY, N.J., Jan. 11, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the launch of an e-commerce shop for patients...